List view / Grid view
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201)…
Priority Review has been granted for [fam-] trastuzumab deruxtecan (DS-8201) for the treatment of HER2-positive metastatic breast cancer.
As part of the 50th Annual Meeting of the American…
2 June 2014 | By AstraZeneca
As part of the 50th Annual Meeting of the American Society for Clinical Oncology (ASCO), Dr Joyce Liu presented data on a Phase II study conducted by the American National Cancer Institute...
SELECT-1 will be the first Phase III study to investigate…
22 October 2013 | By AstraZeneca
SELECT-1 will be the first Phase III study to investigate whether a MEK inhibitor in combination with chemotherapy is superior to chemotherapy alone...
As a result of the initiation of this programme, a…
4 September 2013 | By AstraZeneca
As a result of the initiation of this programme, a pre-tax impairment charge of $285 million will be reversed and the asset restored to our balance sheet in the third quarter of 2013...
